EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study

Andrew Östör, Eugen Feist, Prodromos Sidiropoulos, Jérôme Avouac, Martin Rebella, Rajaie Namas, Frank Buttgereit, Philip G Conaghan, Ana B Romero, Erin L McDearmon-Blondell, Ivan Lagunes-Galindo, Tianming Gao und 3 weitere

Rheumatology and Therapy · 2026-06 · 13 (3) · 659-676

DOI: 10.1007/s40744-026-00826-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Therapy, online erschienen am 19.03.2026. Verfasst von Andrew Östör und 14 weiteren Autor:innen. Beteiligte Einrichtung: Monash University and Emeritus Research, Melbourne, VIC, Australia. andrewostor@gmail.com. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Upadacitinib, an oral Janus kinase inhibitor, has shown a favorable benefit-risk profile in rheumatoid arthritis (RA) clinical trials. This analysis aimed to assess the long-term effectiveness and safety of upadacitinib through 24 months in the UPHOLD real-world observational study. METHODS: The coprimary endpoints were: (1) proportion of patients achieving disease activity score in 28 joints using C-reactive protein (DAS28[CRP]) remission (< 2.6) at 6 months; and (2) proportion of those patients who maintained remission at 12 months. Additional endpoints assessed through 24 months included: achievement and maintenance of DAS28(CRP) low disease activity (LDA; ≤ 3.2); maintenance of response by treatment strategy and prior therapy; disease category by visit; improvements in patient-reported outcomes (PROs); and achievement of glucocorticoid (GC)-free remission. Endpoints were analyzed by modified nonresponder imputation (mNRI) and as observed (AO). Exposure-adjusted event rates (events/100 patient-years [E/100 PY]) for treatment-emergent adverse events (TEAEs) were reported through May 15, 2024. RESULTS: In total, 1029/1715 (60.0%) patients completed the 24-month follow-up. DAS28(CRP) responses at 6 months were well maintained through 24 months (mNRI/AO remission, 62.9%/83.9%; and LDA, 65.7%/90.1%, respectively). Remission rates at 24 months were consistent between patients maintaining combination therapy and those maintaining monotherapy (81.1% and 87.4%, respectively; AO). Responses were also largely similar across prior therapy subgroups. Improvements in PROs achieved by 12 months were maintained through 24 months. Most patients receiving GCs at baseline who achieved GC-free remission maintained GC-free remission at 24 months. Among selected TEAEs of interest, herpes zoster, serious infection, and hepatic disorder occurred at 3.5, 3.1, and 2.6 E/100 PY, respectively. No new safety signals were identified. CONCLUSIONS: Upadacitinib was effective for the long-term treatment of RA in real-world practice, with responses achieved at 6 months maintained through 2 years, and no new safety findings. TRIAL REGISTRATION: NCT04497597.

Schlagwörter

Stichwörter der Autor:innen

EffectivenessReal-worldRheumatoid arthritisSafetyUpadacitinib

Autor:innen und Institutionen

  • Monash University and Emeritus Research, Melbourne, VIC, Australia. andrewostor@gmail.com.
  • Australian National University, Canberra, Australia. andrewostor@gmail.com.
  • Cabrini Medical Centre, Suite 43, 183 Wattletree Rd, Malvern, VIC, 3144, Australia. andrewostor@gmail.com.
  • Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Experimental Rheumatology of the Otto-von-Guericke University, Magdeburg, Germany.
  • Faculty of Medicine, University of Crete, Heraklion, Greece.
  • Service de Rhumatologie, Hôpital Cochin, AP-HP. Centre-Université Paris Cité, Paris, France.

Förderung

  • AbbVie

Zitieren

APA

Östör, A., Feist, E., Sidiropoulos, P., Avouac, J., Rebella, M., Namas, R., Buttgereit, F., Conaghan, P. G., Romero, A. B., McDearmon-Blondell, E. L., Lagunes-Galindo, I., Gao, T., Kadakia, A., Shaw, T., & Attar, S. (2026). Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study. Rheumatology and Therapy, 13(3), 659-676. https://doi.org/10.1007/s40744-026-00826-5

Vancouver

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, et al. Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study. Rheumatology and Therapy. 2026;13(3):659-676. doi:10.1007/s40744-026-00826-5

BibTeX
@article{str2026,
  author = {Östör, Andrew and Feist, Eugen and Sidiropoulos, Prodromos and Avouac, Jérôme and Rebella, Martin and Namas, Rajaie and Buttgereit, Frank and Conaghan, Philip G and Romero, Ana B and McDearmon-Blondell, Erin L and Lagunes-Galindo, Ivan and Gao, Tianming and Kadakia, Aditi and Shaw, Tim and Attar, Suzan},
  title = {Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study},
  journal = {Rheumatology and Therapy},
  year = {2026},
  volume = {13},
  number = {3},
  pages = {659--676},
  doi = {10.1007/s40744-026-00826-5}
}
Kostenlos starten →